Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
Should We Treat High-Risk Smoldering Myeloma, Trials with Daratumumab In Frontline & General Approach for Newly Diagnosed Multiple Myeloma
Comments 0
Login to view comments.
Click here to Login
